MedTrace Logo

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

NCT04839991 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-11-18

No results posted yet for this study

Summary

FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary RP2D.In addition this study will assess the safety and efficacy of CB307 when given in combination with pembrolizumab (KEYTRUDA®) in patients with metastatic PSMA+ castration-resistant cancer

Conditions

  • Advanced and/or Metastatic Solid Tumours

Interventions

DRUG

CB307

Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin

Sponsors & Collaborators

  • Crescendo Biologics Ltd.

    lead INDUSTRY

Principal Investigators

  • K Hashimoto · Crescendo Biologics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-08
Primary Completion
2024-07-25
Completion
2024-09-25
FDA Drug
Yes

Countries

  • United States
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839991 on ClinicalTrials.gov